by | Apr 17, 2024 | Publications
Acta Haematol. 2024 Apr 16. doi: 10.1159/000538658. Online ahead of print. ABSTRACT INTRODUCTION: The definition of primary plasma cell leukemia (pPCL) has been revised from ≥20% to ≥5% circulating plasma cells (CPC). However, the precise prognosis associated with CPC...
by | Apr 17, 2024 | Publications
Arch Biochem Biophys. 2024 Apr 14:109994. doi: 10.1016/j.abb.2024.109994. Online ahead of print. ABSTRACT Interactions between the plasma cells and the BM microenvironment of Multiple myeloma (MM) take place through factors such as exosomes. Many studies have...
by | Apr 17, 2024 | Publications
BMJ Case Rep. 2024 Apr 16;17(4):e257346. doi: 10.1136/bcr-2023-257346. ABSTRACT Extramedullary relapse in patients with multiple myeloma (MM) is often associated with loss of biochemical response and the appearance of measurable residual disease in the bone marrow....
by | Apr 17, 2024 | Publications
Sci Rep. 2024 Apr 16;14(1):8797. doi: 10.1038/s41598-024-58828-8. ABSTRACT Deletions of chromosome 1p (del(1p)) are a recurrent genomic aberration associated with poor outcome in Multiple myeloma (MM.) TRIM33, an E3 ligase and transcriptional co-repressor, is located...
by | Apr 17, 2024 | Publications
Expert Rev Anticancer Ther. 2024 Apr 16. doi: 10.1080/14737140.2024.2344650. Online ahead of print. NO ABSTRACT PMID:38626305 | DOI:10.1080/14737140.2024.2344650
by | Apr 16, 2024 | Publications
Am J Hematol. 2024 Apr 15. doi: 10.1002/ajh.27326. Online ahead of print. ABSTRACT In the phase 2 GRIFFIN trial (ClinicalTrials.gov identifier: NCT02874742), daratumumab added to lenalidomide, bortezomib, and dexamethasone (D-RVd) improved depth of response and...
